How a Google DeepMind Spin-off Hunts Hidden Drug Targets

Summary

For more than a decade, artificial intelligence has been touted as a way to dramatically accelerate drug discovery. Yet despite billions of dollars in investment, relatively few AI-designed medicines have made it to patients. That’s partially because the timelines for careful drug testing can’t be easily compressed—and partially because drug development is just really hard. Isomorphic Labs, the Google DeepMind spin-off that’s building on DeepMind’s Nobel Prize-winning work on protein structure p

SpinGraph analysis pending — check back after processing.

• AI’s Volatile Power Use Quietly Tests Grid Limits
• Nvidia’s AI Hardware Comes to Windows in RTX Spark PCs
• AI Can Help Track the World’s Shrinking Glaciers
• Timing Trick Cuts Energy Used in LLM Training by Up to 14 Percent
• Visual Language Models Train Robots to Read Human Emotions
• General Motors Is Cutting Its Development Cycles in Half